BioCryst Prelim Full Year 2024 ORLADEYO® (berotralstat) Net Revenue $437 Million (+34% y-y)

 —ORLADEYO net revenue expected to be between $515-$535 million in 2025—

—Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025—

—Company achieved operating profit in 2024 (not including stock-based compensation) and expects to approach quarterly EPS profitability/positive cash flow in 2H 2025—

—New drug application planned in 2025 for ORLADEYO granules in children up to age 12; will address significant unmet need—

—Pipeline advancing into patients with Netherton syndrome (BCX17725) and diabetic macular edema (avoralstat) in 2025—

https://www.globenewswire.com/news-release/2025/01/10/3007560/29446/en/BioCryst-Announces-Preliminary-Full-Year-2024-ORLADEYO-berotralstat-Net-Revenue-of-437-Million-34-percent-y-o-y.html